What are the recommended inpatient seizure orders, including medication dosing, monitoring, and laboratory studies, for a patient presenting with seizures?

Inpatient Seizure Orders

For adult patients presenting with seizures, initiate benzodiazepines as first-line treatment (lorazepam preferred), followed immediately by second-line agents (levetiracetam, valproate, or fosphenytoin) if seizures persist after optimal benzodiazepine dosing, with concurrent monitoring for airway protection, vital signs, and investigation of underlying etiology.

Initial Management & Monitoring

Immediate Actions

• Airway, breathing, circulation (ABC) assessment with high-flow oxygen and airway protection interventions as needed 1
• Continuous vital sign monitoring including oxygen saturation
• Establish IV access immediately
• Point-of-care glucose check (treat hypoglycemia if present)
• Cardiac monitoring for dysrhythmias, especially when administering phenytoin/fosphenytoin

Laboratory Studies

Order the following labs immediately:

• Basic metabolic panel (sodium, glucose, calcium, magnesium) to identify metabolic causes 1
• Complete blood count
• Antiseizure medication levels if patient has known epilepsy
• Toxicology screen if substance use or withdrawal suspected
• Liver function tests (baseline before valproate)
• Pregnancy test in women of childbearing age

Consider additional studies based on clinical context:

• Lumbar puncture if CNS infection suspected 2
• Blood cultures if febrile
• Arterial blood gas if respiratory compromise

Medication Orders

First-Line: Benzodiazepines

Lorazepam is the preferred initial agent 1, 3:

• Dose: 0.1 mg/kg IV (maximum 4 mg per dose)
• May repeat after 5 minutes if seizures continue
• Maximum total: 8 mg

Alternative if lorazepam unavailable:

• Diazepam: 10 mg IV, may repeat once

Second-Line Agents (if seizures persist after benzodiazepines)

The evidence supports three equally effective options 1, 4:

Option 1: Levetiracetam (Preferred for safety profile)

• Loading dose: 30-50 mg/kg IV (maximum 2,500-3,000 mg)
• Infusion rate: 100 mg/min
• Maintenance: 500-1,500 mg IV every 12 hours
• Advantages: Minimal hypotension/respiratory depression, no cardiac monitoring required 1
• Side effects: Nausea, rash (rare)

Option 2: Valproate (Preferred if hypotension concern)

• Loading dose: 20-30 mg/kg IV (maximum 3,000 mg)
• Infusion rate: 40 mg/min
• Maintenance: 500-1,000 mg IV every 8-12 hours
• Advantages: No hypotension, effective as phenytoin 1
• Contraindications: Pregnancy, liver disease, thrombocytopenia
• Side effects: Dizziness, thrombocytopenia, hepatotoxicity, hyperammonemia

Option 3: Fosphenytoin

• Loading dose: 18-20 PE/kg IV (maximum 1,500 PE)
• Infusion rate: 100-150 PE/min
• Maintenance: 4-6 mg PE/kg/day divided every 8-12 hours
• Requires cardiac monitoring during infusion 1
• Side effects: Hypotension, cardiac dysrhythmias
• Less preferred than phenytoin due to lower efficacy (56% success rate) 1

Third-Line: Refractory Status Epilepticus

If seizures continue after second-line agent, transfer to ICU and consider 1:

Phenobarbital:

• Loading dose: 10-20 mg/kg IV (maximum 1,000 mg)
• Infusion rate: 50-100 mg/min
• Maintenance: 1-3 mg/kg IV every 12 hours
• Prepare for respiratory depression and hypotension

For intubated patients:

• Midazolam infusion: 0.2 mg/kg bolus, then 0.05-2 mg/kg/hr
• Propofol: 2 mg/kg bolus, then 5 mg/kg/hr infusion (requires intubation) 1

Diagnostic Studies

Neuroimaging

• CT head without contrast emergently if:
  • First seizure
  • Focal neurological deficits
  • Trauma suspected
  • Persistent altered mental status
  • Fever with concern for abscess
• MRI brain with epilepsy protocol for inpatients when stable (preferred over CT for definitive evaluation) 2, 5

Electroencephalography (EEG)

• Continuous EEG monitoring if:
  • Status epilepticus
  • Persistent altered mental status after seizure cessation
  • Concern for nonconvulsive status epilepticus 1, 2
• Routine EEG within 24 hours for first unprovoked seizure 2, 6

Seizure Precautions Orders

• Bed in lowest position with padded side rails up
• Suction and airway equipment at bedside
• Oxygen available
• IV access maintained
• Seizure observation protocol: Document time, duration, description, post-ictal state
• Fall precautions
• Assistance with ambulation

Common Pitfalls

Underdosing benzodiazepines: Ensure full weight-based dosing before declaring failure and moving to second-line agents 1, 4.

Phenytoin infusion errors: Must use cardiac monitoring; infuse no faster than 50 mg/min to avoid cardiac toxicity. Soft tissue injury with extravasation can cause purple glove syndrome 1.

Valproate in pregnancy: Absolutely contraindicated due to teratogenicity 1.

Delayed second-line treatment: Do not wait for benzodiazepine levels to "work"—if seizures persist after 5-10 minutes and repeat benzodiazepine dose, immediately administer second-line agent 1, 4.

Missing underlying etiology: Always search for and treat reversible causes (hypoglycemia, hyponatremia, infection, toxins, withdrawal) concurrently with seizure management 1.

Nuances in Agent Selection

The 2024 ACEP guidelines found no clear superiority among levetiracetam, valproate, and fosphenytoin for second-line treatment 4. However, levetiracetam has emerged as preferred in practice due to superior safety profile with minimal hypotension or respiratory depression 1. Valproate demonstrates equal efficacy to phenytoin with significantly less hypotension (0% vs 12%) 1. The traditional phenytoin/fosphenytoin approach has fallen out of favor given only 56% efficacy and significant adverse effects 1.